Stipple Bio Emerges From Stealth with $100M Series A
vcnewsdaily
2 months ago
63 views
CAMBRIDGE, MA, Stipple Bio, a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, announced the close of a $100 million Series A financing.
Continue Reading
Sign up for FREE to read the full article and access 131K+ alternative investment headlines.